ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Cleveland Diagnostics Receives Support from JobsOhio

November 8, 2021 GMT

CLEVELAND--(BUSINESS WIRE)--Nov 8, 2021--

Cleveland Diagnostics, Inc., a commercial stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, today announced that the company has received support from JobsOhio, a private nonprofit economic development corporation with a mission to drive job creation and new capital investment in Ohio through business attraction, retention, and expansion. Under the agreement, Cleveland Diagnostics is subject to economic development requirements regarding Ohio-based job creation and retention.

ADVERTISEMENT

“We’re proud to have aligned with JobsOhio to expand Cleveland Diagnostics’ local presence and to drive innovation and job opportunities within the area,” said Arnon Chait, PhD, CEO of Cleveland Diagnostics. “We look forward to working together to further support Ohio’s already thriving business community.”

JobsOhio plays a leading role in Ohio’s economic development and serves as a catalyst to accelerate growth by investing in communities, helping local businesses expand and attracting new companies to the state – all contributing to job creation, greater payrolls and more investment.

“Cleveland Diagnostics is an exciting, emerging healthcare company in the region and is a natural partner for JobsOhio, as we continue to work to strengthen the economic base for our state,” said J.P. Nauseef, president and CEO at JobsOhio. “Ohio’s comprehensive network of innovative institutions offers companies the opportunity to collaborate and partner on new discoveries that can further their competitive advantage and impact their respective industries.”

Cleveland Diagnostics’ first product, IsoPSA, is a structure-based prostate cancer test that interrogates the spectrum of structural changes to prostate specific antigen (PSA) thereby effectively differentiating between high-grade prostate cancer and low-grade prostate cancer and benign prostate disease. The company plans to expand its portfolio of non-invasive cancer diagnostics from prostate cancer to breast cancer and lung cancer, and certain neurological diseases.

ADVERTISEMENT

About Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc., is a commercial-stage diagnostics company developing highly efficacious, lab-friendly, affordable diagnostics tests using proprietary technology to improve cancer diagnostics. Its Solvent Interaction Analysis™ (SIA) technology investigates protein biomarkers at the structural level (as opposed to overall biomarker concentration in blood), providing better and more direct insights regarding the protein origin on the cellular level, thus improving test specificity to the underlying disease process. Its portfolio of non-invasive cancer diagnostics will be expanding from prostate cancer to breast cancer and lung cancer, and certain neurological diseases. Visit us at ClevelandDx.com and IsoPSA.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20211108005156/en/

CONTACT: Cleveland Diagnostics, Inc.

Bob Rochelle

Phone: (216) 432-2700, Ext. 2119

Bob.Rochelle@ClevelandDx.com

KEYWORD: OHIO UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH OTHER HEALTH HEALTH ONCOLOGY

SOURCE: Cleveland Diagnostics, Inc.

Copyright Business Wire 2021.

PUB: 11/08/2021 09:00 AM/DISC: 11/08/2021 09:02 AM

http://www.businesswire.com/news/home/20211108005156/en